Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma.
Rasco DW, Medina T, Corrie P, Pavlick AC, Middleton MR, Lorigan P, Hebert C, Plummer R, Larkin J, Agarwala SS, Daud AI, Qiu J, Bozon V, Kneissl M, Barry E, Olszanski AJ. Rasco DW, et al. Among authors: bozon v. Cancer Chemother Pharmacol. 2023 Jul;92(1):15-28. doi: 10.1007/s00280-023-04544-5. Epub 2023 May 23. Cancer Chemother Pharmacol. 2023. PMID: 37219686 Free PMC article. Clinical Trial.
Biased Signaling and Allosteric Modulation at the FSHR.
Landomiel F, De Pascali F, Raynaud P, Jean-Alphonse F, Yvinec R, Pellissier LP, Bozon V, Bruneau G, Crépieux P, Poupon A, Reiter E. Landomiel F, et al. Among authors: bozon v. Front Endocrinol (Lausanne). 2019 Mar 13;10:148. doi: 10.3389/fendo.2019.00148. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 30930853 Free PMC article. Review.
Follicle-Stimulating Hormone Receptor: Advances and Remaining Challenges.
De Pascali F, Tréfier A, Landomiel F, Bozon V, Bruneau G, Yvinec R, Poupon A, Crépieux P, Reiter E. De Pascali F, et al. Among authors: bozon v. Int Rev Cell Mol Biol. 2018;338:1-58. doi: 10.1016/bs.ircmb.2018.02.001. Epub 2018 Apr 5. Int Rev Cell Mol Biol. 2018. PMID: 29699689 Review.
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.
Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V, Bozón V, Long GV, Flaherty K. Dummer R, et al. Among authors: bozon v. Lancet Oncol. 2017 Apr;18(4):435-445. doi: 10.1016/S1470-2045(17)30180-8. Epub 2017 Mar 9. Lancet Oncol. 2017. PMID: 28284557 Clinical Trial.
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.
Dahlman KB, Xia J, Hutchinson K, Ng C, Hucks D, Jia P, Atefi M, Su Z, Branch S, Lyle PL, Hicks DJ, Bozon V, Glaspy JA, Rosen N, Solit DB, Netterville JL, Vnencak-Jones CL, Sosman JA, Ribas A, Zhao Z, Pao W. Dahlman KB, et al. Among authors: bozon v. Cancer Discov. 2012 Sep;2(9):791-7. doi: 10.1158/2159-8290.CD-12-0097. Epub 2012 Jul 13. Cancer Discov. 2012. PMID: 22798288 Free PMC article.
Phase I/II trial of tremelimumab in patients with metastatic melanoma.
Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, Pavlov D, Bulanhagui C, Bozon VA, Gomez-Navarro J, Ribas A. Camacho LH, et al. Among authors: bozon va. J Clin Oncol. 2009 Mar 1;27(7):1075-81. doi: 10.1200/JCO.2008.19.2435. Epub 2009 Jan 12. J Clin Oncol. 2009. PMID: 19139427 Clinical Trial.
29 results